What is the Appropriate Margin Width for a Malignant Phyllodes Tumor

Rodrigo Arrangoiz MS, MD, FACS, FSSO

👉Malignant phyllodes tumors carry a high risk of local recurrence if not excised to wide negative margins.

👉How wide these margins should be is a matter of debate with data supporting a negative margin of any width to a negative margin as wide as 2 cm.

👉Currently, the National Comprehensive Cancer Network recommends a margin width of 1cm; however, recent studies suggest margin width is not associated with local recurrence or local recurrence free survival.

👉The addition of radiation therapy when margins are closer than 1 cm or other high-risk features are present can also be a consideration but it is controversial.

👉Most data indicate unacceptably high recurrence rates if the tumor is at the inked margin of a malignant phyllodes tumor excision.

👉Mastectomy is not required unless excision cannot achieve tumor-free margins.

👉The most appropriate margin thickness for borderline or benign phyllodes tumors is even less well-defined.

👉Although achieving widely negative margins can reduce local recurrence rates, malignant phyllodes tumors also have metastatic potential regardless of negative margin status. 

👉REFERENCES

  1. Belkacémi Y, Bousquet G, Marsiglia H, et al. Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys. 2008;70:492-500.
  2. Jang JH, Choi MY, Lee SK, et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Ann Surg Oncol. 2012;19:2612-2617. 
  3. Mituś J, Reinfuss M, Mituś JW, et al. Malignant phyllodes tumor of the breast: treatment and prognosis. Breast J.2014;20:639-644. 
  4. Petrek J. Phyllodes tumors. In: Harris JR, Lippman ME, Morrow M, et al. eds. Diseases of the Breast, 2nd ed. Philadelphia PA: Lippincott-Raven Publishers, 2000:669-675.
  5. Telli ML, Horst KC, Guardino AE, et al. Phyllodes tumors of the breast: natural history, diagnosis, and treatment. J Natl Compr Canc Netw. 2007;5:324-330. 
  6. Yom CK, Han W, Kim SW, et al. Reappraisal of conventional risk stratification for local recurrence based on clinical outcomes in 285 resected phyllodes tumors of the breast. Ann Surg Oncol. 2015;22:2912-2918.

#Arrangoiz #PhyllodesTumors

#Surgeon #MountSinaiMedicalCenter #MSMC #Miami #Mexico

#Cirujano

#SurgicalOncologist

#CirujanoOncologo

#BreastSurgeon

#CirujanodeMama

#CancerSurgeon

#CirujanodeCancer

Unknown's avatar

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a comment